Lizogub Viktor G., Riley David S., Heger Marianne
Explore, 2007
Abstract
Background
The common cold is a viral infection with symptoms such as sneezing, sore throat, and running nose. It is one of the most prevalent illnesses in the world, and although commonly caused by rhinoviruses, antibiotics are often prescribed unnecessarily. Therefore, it is of utmost importance to evaluate alternative treatments such as herbal medications, whose efficacy and safety is proven by pharmacological and clinical studies.
Objective
The aim of the present study was to evaluate the efficacy of a liquid herbal drug preparation from the roots of Pelargonium sidoides compared with placebo in adult patients with the common cold.
Design
The study was designed as a multicenter, prospective, randomized, double blind, parallel group, placebo-controlled phase III clinical trial with an adaptive group-sequential design.
Setting
The study took place in eight outpatient departments affiliated with hospitals.
Patients
One hundred three male and female adult patients with at least two major and one minor or with one major and three minor cold symptoms (maximum symptom score of 40 points), present for 24 to 48 hours, and who gave provision of informed consent were randomized to receive either 30 drops (1.5 mL) of the liquid herbal drug preparation EPs or placebo three times a day.
Intervention
Patients received randomized treatment for a maximum period of 10 days. Measurements: The primary outcome criterion was the sum of symptom intensity differences (SSID) of the cold intensity score (CIS) from day one to day five. The CIS consists of the following 10 cold symptoms: nasal drainage, sore throat, nasal congestion, sneezing, scratchy throat, hoarseness, cough, headache, muscle aches, and fever.
Results
From baseline to day five, the mean SSID improved by 14.6 +/- 5.3 points in the EPs group compared with 7.6 +/- 7.5 points in the placebo group. This difference was statistically significant (P < .0001). The mean CIS decreased by 10.4 +/- 3.0 points and 5.6 +/- 4.3 points in EPs and placebo-treated patients, respectively. After 10 days, 78.8% versus 31.4% in the EPs versus placebo group were clinically cured (CIS equals zero points or complete resolution of all but a maximum of one cold symptom; P < .0001). The mean duration of inability to work was significantly lower in the EPs treatment group (6.9 +/- 1.8 days) than in the placebo group (8.2 +/- 2.1 days; P = .0003). Treatment outcome (rates of complete recovery or major improvement from disease [integrative medicine outcomes scale]) was assessed better in the EPs treatment group than in the placebo group by both the investigator and the patient on day five (P < .0001). Adverse events occurred in three of 103 patients (2.9%), with two of 52 (3.8%) and one of 51 (2.0%) patients in the EPs and placebo group, respectively. All adverse events were assessed as nonserious. At the end of treatment, all patients (100%) in the active treatment group judged the subjective tolerability of EPs as good or very good.
Conclusions
EPs represents an effective treatment of the common cold. It significantly reduces the severity of symptoms and shortens the duration of the common cold compared with placebo. The herbal drug is well tolerated.
| PMID: | 18005909 |
|---|---|
| DOI: | 10.1016/j.explore.2007.09.004 |
| Category: | Cold / Flu |
Articles similar to "Efficacy of a Pelargonium Sidoides Preparation in Patients With the Common Cold: A Randomized, Double Blind, Placebo-Controlled Clinical Trial."
- The significance of Pelargonium Sidoides for Cold / Flu: Efficacy of Proanthocyanidins From Pelargonium sidoides Root Extract in Reducing P. gingivalis Viability While Preserving Oral Commensal S. salivarius. (Bacterial resistance to antibiotics and the disruption of beneficial microbiota are key problems in contemporary medicine and make the search for new, more efficient infection treatment strategies among the most important tasks in medicine...)
- The role of Pelargonium Sidoides in Cold / Flu: Investigation of Antibacterial and Antiinflammatory Activities of Proanthocyanidins From Pelargonium sidoides DC Root Extract. (The study explores antibacterial, antiinflammatory and cytoprotective capacity of Pelargonium sidoides DC root extract (PSRE) and proanthocyanidin fraction from PSRE (PACN) under conditions characteristic for periodontal disease...)
- The impact of Pelargonium Sidoides on Cold / Flu: The Pelargonium Sidoides Extract EPs 7630 Drives the Innate Immune Defense by Activating Selected MAP Kinase Pathways in Human Monocytes. (Pelargonium sidoides is a medical herb and respective extracts are used very frequently for the treatment of respiratory tract infections...)
- The significance of Pelargonium Sidoides for Cold / Flu: The Efficacy of Pelargonium Sidoides in the Treatment of Upper Respiratory Tract Infections in Children With Transient Hypogammaglobulinemia of Infancy. (Transient hypogammaglobulinemia of infancy (THI), defined as prolongation of physiological hypogammaglobulinemia normally seen between the initial 3rd and 6th months of life, is one of the most common immune deficiencies of childhood...)
- The impact of Pelargonium Sidoides on Cold / Flu: Efficacy and Tolerability of EPs 7630 Tablets in Patients With Acute Bronchitis: A Randomised, Double-Blind, Placebo-Controlled Dose-Finding Study With a Herbal Drug Preparation From Pelargonium Sidoides. (Objective: Acute bronchitis is one of the most frequent health complaints for which patients seek medical advice... This study demonstrated statistically significant and clinically relevant superiority of all three tested dosages of EPs 7630 over placebo. All dosages of EPs 7630 were well-tolerated. Taking into account both efficacy and safety, the results of this study indicate that the 20 mg tablets of EPs 7630 taken three times daily constitute the optimal dose with respect to the benefit-risk ratio.)
- The significance of Pelargonium Sidoides for Cold / Flu: Treatment of Acute Bronchitis in Adults With a Pelargonium Sidoides Preparation (EPs® 7630): A Randomized, Double-Blind, Placebo-Controlled Trial. ( Acute bronchitis is a widespread medical problem, and, although predominantly caused by viruses, antibiotics are still prescribed unnecessarily... EPs 7630 was superior in efficacy compared with placebo in the treatment of adults with acute bronchitis. It may therefore offer an effective alternative for acute bronchitis unless antibiotics are clearly indicated.)